Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest DNA vaccination Stories

2012-03-07 11:30:00

ATLANTA, March 7, 2012 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotech company specializing in the development of HIV/AIDS vaccines, announced the results of a study suggesting that scientists may be one step closer to a vaccine that protects against multiple exposures to HIV infections. The study results were unveiled by Dr. Robinson during a presentation in Seattle at the 2012 Conference on...

2012-03-05 03:00:00

BLUE BELL, Pa., March 5, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) announced today that its SynCon® therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice. This vaccine is complementary to Inovio's VGX-3100, a therapeutic vaccine targeting cervical dysplasias and cancers caused by HPV types 16 and...

2012-03-01 01:58:17

Very recently, researchers discovered an important population of immune cells called memory T cells living in parts of the body that are in contact with the environment (e.g., skin, lung, GI tract). How these "resident" memory T cells are generated was unknown, and their importance with regard to how our immune system remembers infection and how it prevents against re-infection is being studied intensively. Now, a study by a Brigham and Women's Hospital (BWH) research team led by Xiaodong...

2012-03-01 01:54:36

Research shows for the first time that resident memory T cells prevalent in the skin are more protective in fighting infection than central memory T cells in the bloodstream TREM Rx, Inc., a biotechnology company with a proprietary technology platform for novel vaccines delivered to the skin, announced today the results of an in vivo preclinical study that shows, for the first time, that powerful cells of the immune system called TREMs (T Resident Effector Memory cells) prevalent in the...

2012-02-22 03:00:00

BLUE BELL, Pa., Feb. 22, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that its next generation surface skin electroporation technology was successfully used to significantly enhance the delivery of small interfering RNA (siRNA) molecules to skin in animal studies. The data was published in the journal Molecular Therapy - Nucleic Acids in a paper entitled, "Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface...

2012-02-21 03:00:00

BLUE BELL, Pa., Feb. 21, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that David B. Weiner, Ph.D., Professor, Department of Pathology & Laboratory Medicine, University of Pennsylvania, and Chairman of Inovio's Scientific Advisory Board, has been elected a fellow in the American Association for the Advancement of Science (AAAS). Dr. Weiner, often called the "father of synthetic DNA vaccines," is being honored for his pioneering and enabling discoveries...

2012-01-23 10:36:20

Researchers at Duke University Medical Center have created synthetic nanoparticles that target lymph nodes and greatly boost vaccine responses, said lead author Ashley St. John, Ph.D., a researcher at Duke-NUS Graduate Medical School. The paper was published online in the journal Nature Materials on Jan. 22. Currently all other adjuvants (substances added to vaccines to help to boost the immune response) are thought to enhance immunity at the skin site where the vaccine is injected...

2011-11-17 03:00:00

BLUE BELL, Pa., Nov. 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon® avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines. This...

2011-11-07 03:00:00

BLUE BELL, Pa., Nov. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended September 30, 2011. Total revenue was $2.6 million and $8.2 million for the three and nine months ended September 30, 2011, compared to $1.3 million and $3.8 million for the same periods in 2010. Total operating expenses for the three and nine months ended September 30, 2011, were $9.0 million and $24.0 million as compared to $5.8 million and...

2011-10-10 03:00:00

BLUE BELL, Pa., Oct. 10, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc. (KSE:011000), to co-develop Inovio's SynCon® therapeutic vaccines for hepatitis B and C infections. Under the terms of the agreement, VGX International will...